Following the observation that the gp120 monomers bound to cell-surface CD4 displayed the CD4i epitope, we obtained serum samples from the VaxGen Inc phase III clinical trial now licensed to the Global Solutions for Infectious Diseases. Here, CD4 is linked to infectious disease.